TAXUS ARRIVE 2: A multi-center safety surveillance program
Phase of Trial: Phase IV
Latest Information Update: 15 Nov 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ARRIVE-2
- Sponsors Boston Scientific Corporation
- 25 Sep 2008 Status changed from active, no longer recruiting to completed.
- 13 May 2008 Pooled analysis of 2-year outcomes for 7,492 patients in the ARRIVE 1 and 2 registries reported at EuroPCR 2008.
- 29 Mar 2008 Pooled analysis of 2-year outcomes for 7,033 patients in the ARRIVE 1 and 2 registries reported at SCAI-ACCi2 2008.